why choose us

First received: November 02, 2023

Clinical Trial: Impact GLP-1 Agonists Following Bariatric

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Morbid Obesity

Study Type: OBSERVATIONAL


Official Title: Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Brief Summary: Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person.GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.Bariatric surgical procedures have been shown to be effective in treating obesity as well as superior to…

Read more